Summary

Eligibility
for people ages 18-99 (full criteria)
Location
at Orange, California and other locations
Dates
study started
completion around

Description

Summary

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).

Official Title

EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction

Keywords

Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization, Acute Myocardial Infarction, Evolocumab, STEMI, NSTEMI, Heart Attack, Pragmatic, Cardiovascular Diseases, Infarction, Routine Lipid Management, Evolocumab + Routine Lipid Management

Eligibility

You can join if…

Open to people ages 18-99

  • Age greater than or equal to 18 years
  • Hospitalized for primary reason of NSTEMI or STEMI due to presumed atherosclerotic disease

You CAN'T join if...

  • Participants requiring invasive hemodynamic and/or vasopressor/inotropic support at the time of screening
  • Participants with elevated biomarkers of myocardial injury due to secondary/nonatherosclerotic etiology (eg, sepsis, atrial fibrillation, vasospasm, decompensated heart failure, uncontrolled hypertension, stress induced cardiomyopathy)

Locations

  • University of California-Irvine accepting new patients
    Orange California 92868 United States
  • VA Greater Los Angeles Healthcare System accepting new patients
    Los Angeles California 90073 United States
  • University of California Los Angeles accepting new patients
    Los Angeles California 90095 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT05284747
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 6000 study participants
Last Updated